

## Abstract

Alteration in dopaminergic and serotonergic neurotransmission influences various neurological and mental disorders such as depression, anxiety, bipolar disorder, schizophrenia and drug abuse. The naturally occurring aporphine alkaloids are well known for their activity at D<sub>1</sub>, D<sub>2</sub> and 5-HT<sub>1A</sub> receptors, but only a few have been shown to bind to the 5-HT<sub>2A</sub> receptor. Aim of this study was to identify aporphines with significant activity at dopamine and serotonin receptors using both *in silico* and *in vitro* screening approaches. A 3D homology model of the rat 5-HT<sub>2A</sub> receptor was generated using the crystal structure of the human  $\beta_2$ -adrenergic receptor (PDB ID: 2RH1) and validated with standard 5-HT<sub>2A</sub> receptor ligands. A filtered set of aporphines obtained from the ZINC database using (*S*)-boldine as the backbone structure was docked into the generated 5-HT<sub>2A</sub> receptor model. A set of 13 compounds were identified with higher or comparable activity to (*S*)-boldine for experimental testing across the D<sub>1</sub>, D<sub>2</sub>, 5-HT<sub>1A</sub> and 5-HT<sub>2A</sub> receptors using a medium throughput radioligand receptor binding assay. (*R*)-roemerine was found to have selective 5-HT<sub>2A</sub> binding affinity with 20–400-fold higher affinity for the 5-HT<sub>2A</sub> receptor versus the D<sub>1</sub>, D<sub>2</sub>, and 5-HT<sub>1A</sub> receptors. Investigation into the structures of the selected compounds revealed that substitution at positions 1 and 2, particularly with a methylenedioxy group, non-substitution at positions 10 and 11 and a protonated amino group at position 6 may be responsible for the good affinity-selectivity profile of (*R*)-roemerine for the 5-HT<sub>2A</sub> receptor compared to the other compounds. Further analysis of the binding modes of the selected compounds also showed that the combination of an electrostatic interaction and the hydrogen bonding between the protonated amino group of (*R*)-roemerine and Asp155 and a pi-cation interaction with Phe339 appears to explain its enhanced affinity and selectivity as compared to the other compounds. The results illustrate the usefulness of a

combined *in silico* and *in vitro* approach in the search for lead molecules for the development of new selective drugs acting at dopamine and serotonin receptors.

## Abstrak

Perubahan pada neurotransmisi dopamin dan serotonin mempengaruhi pelbagai gangguan neurologi dan mental seperti kemurungan, keresahan, gangguan bipolar, skizofrenia dan penyalahgunaan dadah. Alkaloid aporphine semulajadi terkenal dengan aktiviti pada reseptor  $D_1$ ,  $D_2$  dan  $5-HT_{1A}$ , tetapi hanya sebilangan daripadanya menunjukkan ikatan pada reseptor  $5-HT_{2A}$ . Tujuan kajian ini adalah untuk mengenalpasti aporphine dengan aktiviti yang signifikan pada reseptor dopamin dan serotonin menggunakan kedua-dua pendekatan *in silico* dan *in vitro*. Satu model homologi 3D bagi reseptor tikus  $5-HT_{2A}$  telah dijana dengan menggunakan struktur kristal reseptor manusia  $\beta_2$ -adrenergik (PDB ID: 2RH1) dan divalidasi dengan ligan asas  $5-HT_{2A}$ . Satu set aporphines yang ditapis diperoleh dari pangkalan data ZINC dengan menggunakan (*S*)-boldine sebagai struktur asas untuk didok dalam reseptor  $5-HT_{2A}$  yang telah dijana. Sebanyak 13 kompaun telah dikenalpasti dengan aktiviti yang lebih tinggi atau setanding dengan (*S*)-boldine untuk diuji secara experimental pada reseptor  $D_1$ ,  $D_2$ ,  $5-HT_{1A}$  dan  $5-HT_{2A}$  dengan pengendalian asei reseptor radioligan. (*R*)-roemerine menunjukkan ikatan afiniti yang selektif pada reseptor  $5-HT_{2A}$  dengan 20–400-kali ganda lebih tinggi untuk reseptor  $5-HT_{2A}$  berbanding dengan reseptor  $D_1$ ,  $D_2$  dan  $5-HT_{1A}$ . Kajian menyeluruh bagi struktur kompaun yang terpilih menunjukkan bahawa (*R*)-roemerine dengan penggantian pada kedudukan 1 dan 2, khususnya dengan kumpulan metilenadioksi, tanpa penggantian pada kedudukan 10 dan 11 dan kumpulan amino berproton pada kedudukan 6 bertanggungjawab kepada profil afiniti-selektiviti yang baik oleh (*R*)-roemerine bagi reseptor  $5-HT_{2A}$  berbanding kompaun lain. Analisis lanjutan bagi jenis interaksi oleh kompaun terpilih juga menunjukkan bahawa gabungan interaksi elektrostatik dan ikatan hidrogen antara kumpulan amino berproton dalam (*R*)-roemerine dan Asp155 dan interaksi pi-kation dengan Phe339 menjurus kepada

peningkatan afiniti dan selektiviti berbanding dengan kompaun lain. Keputusan ini menunjukkan kepentingan gabungan kedua-dua kaedah *in silico* dan *in vitro* dalam pencarian molekul baru bagi perkembangan ligan yang selektif yang bertindak pada reseptor dopamin dan serotonin.

## **Acknowledgements**

First and foremost, I'm indebted to my supervisors, Prof. Dr. Chung Lip Yong and Dr. Michael James Christopher Buckle for their support, guidance and encouragement throughout this project. I'm thankful to Prof. Dr. Stephen Doughty for his comments and guidance, especially in molecular modelling.

I wish to express my special and sincere thanks to Dr. Azura and all the staff from the animal house for their assistance. I would also like to acknowledge the help of all the staff from Department of Pharmacy and Department of Molecular Medicine. I wish to thank my labmates and friends for their support and friendship.

I sincerely thank to Ministry of Science, Technology and Innovation, Malaysia for the National Science Fellowship award (Ref No: M/0138/02/2008/LAIN2) and University of Malaya for the research grants (PPP vote: PS192/2009C; UMRG: RG009/09BIO).

At last but not the least I would like to thank my beloved family for their undying support, love and blessings, and finally to God who made all the things possible.

# Table of Contents

<b>Title page</b>	i
<b>Abstract</b>	ii
<b>Abstrak</b>	iv
<b>Acknowledgements</b>	vi
<b>Table of Contents</b>	vii
<b>List of Figures</b>	xii
<b>List of Tables</b>	xviii
<b>List of Symbols and Abbreviations</b>	xix
<b>1.0 Introduction</b>	1
1.1 Aim and Objectives of the Research	3
<b>2.0 Literature Review</b>	
2.1 G-Protein Coupled Receptors (GPCRs)	4
2.1.1 G-Protein Coupled Receptor (GPCR) Overview	4
2.1.2 G-Protein Coupled Receptor (GPCR) Crystal Structures	6
2.2 Dopamine (D) and Serotonin (5-hydroxytryptamine; 5-HT) Receptors	8
2.2.1 Dopamine (D) Receptors	8
2.2.2 Serotonin (5-hydroxytryptamine; 5-HT) Receptors	8
2.2.3 Clinical Significance of Dopamine and Serotonin Receptors	9
2.3 Computer Aided Drug Design	11
2.3.1 Structure-Based Drug Design (SBDD)	11
2.3.2 Homology Modelling	11
2.3.3 Molecular Docking	14
2.4 Receptor Binding Assays	14
2.4.1 Fundamental of Receptor–ligand Interactions	14

2.4.2	Radioligand Receptor Binding Assays	15
2.5	Aporphine Alkaloids	16
2.5.1	An Overview of Aporphines	16
2.5.2	Structural Diversity of Aporphines	17
2.5.3	Pharmacological Properties of Aporphines	17
<b>3.0</b>	<b>Computational Investigation of the 5-HT<sub>2A</sub> Receptor Binding Interactions of Standard Ligands and Aporphines</b>	
3.1	Introduction	20
3.1.1	5-HT <sub>2A</sub> Receptor (5-HT <sub>2A</sub> R) Structure	20
3.2	Materials	22
3.3	Methodology	22
3.3.1	Sequence Alignments	22
3.3.2	Model Construction	22
3.3.3	Docking Procedure	23
3.3.4	Compound Selection for Docking	23
3.4	Results and Discussion	25
3.4.1	Selection of Templates	25
3.4.2	Sequence Analysis	25
3.4.3	Model Construction	26
3.4.4	Model Evaluation	26
3.4.5	Docking	27
3.4.6	Compound Selection from Docking Studies	28
3.5	Conclusion	31
<b>4.0</b>	<b>Optimisation and Evaluation of Filtration Based Receptor Binding Assays for Dopamine (D<sub>1</sub> and D<sub>2</sub>) and 5-Hydroxytryptamine (5-HT<sub>1A</sub> and 5-HT<sub>2A</sub>)</b>	

4.1	Introduction	32
4.1.1	Properties of Receptor Binding Assays	32
4.1.2	Selection of Receptor Source	33
4.1.3	Selection of Radioligand	34
4.2	Materials	37
4.2.1	Chemicals and Instrumentation	37
4.3	Methodology	38
4.3.1	Preparation of Dopamine (D <sub>1</sub> and D <sub>2</sub> ) and 5-Hydroxytryptamine (5-HT <sub>1A</sub> and 5-HT <sub>2A</sub> ) Membrane Receptors	38
4.3.2	Protein Determination	40
4.3.3	Receptor binding assays	40
4.3.3.1	Optimisation of Dopamine (D <sub>1</sub> and D <sub>2</sub> ) and 5- Hydroxytryptamine (5-HT <sub>1A</sub> and 5-HT <sub>2A</sub> ) Receptor Binding Assays	40
4.3.3.2	Saturation experiments	41
4.3.3.3	Competition experiments	42
4.3.3.4	Z' factor	42
4.4	Data and Statistical Analysis	44
4.5	Results and Discussion	45
4.5.1	Protein determination	45
4.5.2	Effects of Different Physico-Chemical Properties on Dopamine (D <sub>1</sub> and D <sub>2</sub> ) and 5-Hydroxytryptamine (5-HT <sub>1A</sub> and 5-HT <sub>2A</sub> ) Receptor Binding Assays	45
4.5.2.1	Selection of Membrane Concentration	46
4.5.2.2	Selection of Unlabelled Ligand and its Concentration	47



4.5.2.3	Selection of pH	47
4.5.2.4	Selection of Filter Plate Type	48
4.5.2.5	Selection of Incubation Temperature	49
4.5.2.6	Selection of Incubation Time	50
4.5.2.7	Selection of Washing Times	50
4.5.2.8	Solvent Interference	51
4.5.2.9	Saturation Experiments	56
4.5.2.10	Competition Experiments	57
4.5.2.11	Z' factor	60
4.6	Conclusion	61
<b>5.0</b>	<b>Virtual and Biomolecular Screening of Potential Ligands for 5-HT<sub>2A</sub> Receptor</b>	
5.1	Introduction	63
5.1.1	Structure Activity Relationship (SAR) of Aporphines	63
5.2	Materials	65
5.3	Methodology	65
5.3.1	Receptor Binding Assays	65
5.4	Results and Discussion	66
5.4.1	Receptor Binding Assays	66
5.5	Conclusion	76
<b>6.0</b>	<b>General Conclusion, Limitations and Future Perspectives</b>	77
<b>7.0</b>	<b>References</b>	79
<b>8.0</b>	<b>Appendices</b>	98
A	Sequence Analysis	98
B	Ramachandran Plot	105
C	Binding Modes of Standard Ligands in 5-HT <sub>2A</sub> Receptor Model	106

D	ZINC IDs and the Corresponding Compound Names	112
E	Binding Modes of the Selected Aporphines with the 5-HT <sub>2A</sub> Receptor Model	113
F	Abstracts of Research Presentations	119

## List of Figures

<b>Figure 2.1</b>	Schematic diagram of GPCRs with seven transmembrane regions (TM1–TM7) connected by intracellular and extracellular loop segments, as well as an extracellular N-terminus and an intracellular C-terminus	6
<b>Figure 2.2</b>	Accuracy and application of protein structure models	13
<b>Figure 2.3</b>	General structure of aporphines	17
<b>Figure 2.4</b>	Structures of aporphines	19
<b>Figure 3.1</b>	General structure of naturally-occurring aporphines with possible substitution sites indicated as R <sub>1</sub> –R <sub>11</sub>	24
<b>Figure 3.2</b>	Proposed binding mode of ( <i>S</i> )-boldine in the 5-HT <sub>2A</sub> receptor	30
<b>Figure 4.1</b>	Diagrammatic representations of dissection procedure for rat brain	39
<b>Figure 4.2</b>	Standard curve of BSA concentration against absorbance for use in protein determination	45
<b>Figure 4.3(a)</b>	Selection of membrane concentration for D <sub>1</sub> receptor	52
<b>Figure 4.4(a)</b>	Selection of membrane concentration for D <sub>2</sub> receptor	53
<b>Figure 4.5(a)</b>	Selection of membrane concentration for 5-HT <sub>1A</sub> receptor	54
<b>Figure 4.6(a)</b>	Selection of membrane concentration for 5-HT <sub>2A</sub> receptor	55
<b>Figure 4.3(b)</b>	Selection of unlabelled ligand concentration for D <sub>1</sub> receptor	52
<b>Figure 4.4(b)</b>	Selection of unlabelled ligand concentration for D <sub>2</sub> receptor	53
<b>Figure 4.5(b)</b>	Selection of unlabelled ligand concentration for 5-HT <sub>1A</sub> receptor	54
<b>Figure 4.6(b)</b>	Selection of unlabelled ligand concentration for 5-HT <sub>2A</sub> receptor	55

<b>Figure 4.3(c)</b>	Selection of pH for D <sub>1</sub> receptor	52
<b>Figure 4.4(c)</b>	Selection of pH for D <sub>2</sub> receptor	53
<b>Figure 4.5(c)</b>	Selection of pH for 5-HT <sub>1A</sub> receptor	54
<b>Figure 4.6(c)</b>	Selection of pH for 5-HT <sub>2A</sub> receptor	55
<b>Figure 4.3(d)</b>	Selection of filter plate type for D <sub>1</sub> receptor	52
<b>Figure 4.4(d)</b>	Selection of filter plate type for D <sub>2</sub> receptor	53
<b>Figure 4.5(d)</b>	Selection of filter plate type for 5-HT <sub>1A</sub> receptor	54
<b>Figure 4.6(d)</b>	Selection of filter plate type for 5-HT <sub>2A</sub> receptor	55
<b>Figure 4.3(e)</b>	Selection of incubation temperature for D <sub>1</sub> receptor	52
<b>Figure 4.4(e)</b>	Selection of incubation temperature for D <sub>2</sub> receptor	53
<b>Figure 4.5(e)</b>	Selection of incubation temperature for 5-HT <sub>1A</sub> receptor	54
<b>Figure 4.6(e)</b>	Selection of incubation temperature for 5-HT <sub>2A</sub> receptor	55
<b>Figure 4.3(f)</b>	Selection of incubation time for D <sub>1</sub> receptor	52
<b>Figure 4.4(f)</b>	Selection of incubation time for D <sub>2</sub> receptor	53
<b>Figure 4.5(f)</b>	Selection of incubation time for 5-HT <sub>1A</sub> receptor	54
<b>Figure 4.6(f)</b>	Selection of incubation time for 5-HT <sub>2A</sub> receptor	55
<b>Figure 4.3(g)</b>	Selection of washing times for D <sub>1</sub> receptor	52
<b>Figure 4.4(g)</b>	Selection of washing times for D <sub>2</sub> receptor	53
<b>Figure 4.5(g)</b>	Selection of washing times for 5-HT <sub>1A</sub> receptor	54
<b>Figure 4.6(g)</b>	Selection of washing times for 5-HT <sub>2A</sub> receptor	55
<b>Figure 4.3(h)</b>	Selection of DMSO effect for D <sub>1</sub> receptor	52
<b>Figure 4.4(h)</b>	Selection of DMSO effect for D <sub>2</sub> receptor	53
<b>Figure 4.5(h)</b>	Selection of DMSO effect for 5-HT <sub>1A</sub> receptor	54
<b>Figure 4.6(h)</b>	Selection of DMSO effect for 5-HT <sub>2A</sub> receptor	55
<b>Figure 4.7(a)</b>	Saturation binding curve of [ <sup>3</sup> H] SCH23390 for D <sub>1</sub> receptor	56
<b>Figure 4.7(b)</b>	Saturation binding curve of [ <sup>3</sup> H] spiperone for D <sub>2</sub> receptor	56

<b>Figure 4.7(c)</b>	Saturation binding curve of [ <sup>3</sup> H] 8-OH-DPAT for 5-HT <sub>1A</sub> receptor	56
<b>Figure 4.7(d)</b>	Saturation binding curve of [ <sup>3</sup> H] ketanserin for 5-HT <sub>2A</sub> receptor	56
<b>Figure 4.8(a)</b>	Competition binding curve of [ <sup>3</sup> H] SCH23390 for D <sub>1</sub> receptor	57
<b>Figure 4.8(b)</b>	Competition binding curve of [ <sup>3</sup> H] spiperone for D <sub>2</sub> receptor	57
<b>Figure 4.8(c)</b>	Competition binding curve of [ <sup>3</sup> H] 8-OH-DPAT for 5-HT <sub>1A</sub> receptor	57
<b>Figure 4.8(d)</b>	Competition binding curve of [ <sup>3</sup> H] ketanserin for 5-HT <sub>2A</sub> receptor	57
<b>Figure 4.9(a)</b>	Z' analysis for D <sub>1</sub> receptor	60
<b>Figure 4.9(b)</b>	Z' analysis for D <sub>2</sub> receptor	60
<b>Figure 4.9(c)</b>	Z' analysis for 5-HT <sub>1A</sub> receptor	60
<b>Figure 4.9(d)</b>	Z' analysis for 5-HT <sub>2A</sub> receptor	60
<b>Figure 5.1(a)</b>	Competition binding curves of ( <i>R</i> )-roemerine towards [ <sup>3</sup> H] SCH23390 for D <sub>1</sub> receptor, [ <sup>3</sup> H] spiperone for D <sub>2</sub> receptor, [ <sup>3</sup> H] 8-OH-DPAT for 5-HT <sub>1A</sub> receptor and [ <sup>3</sup> H] ketanserin for 5-HT <sub>2A</sub> receptor	68
<b>Figure 5.1(b)</b>	Competition binding curves of ( <i>S</i> )-bulbocapnine towards [ <sup>3</sup> H] SCH23390 for D <sub>1</sub> receptor, [ <sup>3</sup> H] spiperone for D <sub>2</sub> receptor, [ <sup>3</sup> H] 8-OH-DPAT for 5-HT <sub>1A</sub> receptor and [ <sup>3</sup> H] ketanserin for 5-HT <sub>2A</sub> receptor	68
<b>Figure 5.1(c)</b>	Competition binding curves of ( <i>S</i> )-boldine towards [ <sup>3</sup> H] SCH23390 for D <sub>1</sub> receptor, [ <sup>3</sup> H] spiperone for D <sub>2</sub> receptor, [ <sup>3</sup> H] 8-OH-DPAT for 5-HT <sub>1A</sub> receptor and [ <sup>3</sup> H] ketanserin for 5-HT <sub>2A</sub> receptor	68

<b>Figure 5.1(d)</b>	Competition binding curves of ( <i>R</i> )-apomorphine towards [ <sup>3</sup> H] SCH23390 for D <sub>1</sub> receptor, [ <sup>3</sup> H] spiperone for D <sub>2</sub> receptor, [ <sup>3</sup> H] 8-OH-DPAT for 5-HT <sub>1A</sub> receptor and [ <sup>3</sup> H] ketanserin for 5-HT <sub>2A</sub> receptor	68
<b>Figure 5.1(e)</b>	Competition binding curves of ( <i>S</i> )-apomorphine towards [ <sup>3</sup> H] SCH23390 for D <sub>1</sub> receptor, [ <sup>3</sup> H] spiperone for D <sub>2</sub> receptor, [ <sup>3</sup> H] 8-OH-DPAT for 5-HT <sub>1A</sub> receptor and [ <sup>3</sup> H] ketanserin for 5-HT <sub>2A</sub> receptor	68
<b>Figure 5.1(f)</b>	Competition binding curves of <i>N</i> -propylapomorphine towards [ <sup>3</sup> H] SCH23390 for D <sub>1</sub> receptor, [ <sup>3</sup> H] spiperone for D <sub>2</sub> receptor, [ <sup>3</sup> H] 8-OH-DPAT for 5-HT <sub>1A</sub> receptor and [ <sup>3</sup> H] ketanserin for 5-HT <sub>2A</sub> receptor	68
<b>Figure 5.2</b>	Proposed binding mode of ( <i>R</i> )-roemerine in the 5-HT <sub>2A</sub> receptor	71
<b>Figure 8.1</b>	Alignment of rat 5-HT family receptor	98
<b>Figure 8.2</b>	Sequence alignment of 5-HT <sub>2A</sub> multiple species	101
<b>Figure 8.3</b>	Sequence comparison of rat 5-HT <sub>2A</sub> against human 5-HT <sub>2A</sub>	103
<b>Figure 8.4</b>	Sequence comparison of rat 5-HT <sub>2A</sub> against rat 5-HT <sub>2B</sub> and 5-HT <sub>2C</sub> sequences	104
<b>Figure 8.5</b>	Structure validation of the model using Ramachandran plot computed with the PROCHECK program	105
<b>Figure 8.6(a)</b>	The 5-HT <sub>2A</sub> receptor model in complex with endogenous ligand, serotonin	106
<b>Figure 8.6(b)</b>	The 5-HT <sub>2A</sub> receptor model in complex with tryptamine	106
<b>Figure 8.6(c)</b>	The 5-HT <sub>2A</sub> receptor model in complex with 5-MeOT	107
<b>Figure 8.6(d)</b>	The 5-HT <sub>2A</sub> receptor model in complex with ( <i>R</i> )-(-)-DOI	107

<b>Figure 8.6(e)</b>	The 5-HT <sub>2A</sub> receptor model in complex with ( <i>S</i> )-(-)-DOI	108
<b>Figure 8.7(a)</b>	The 5-HT <sub>2A</sub> receptor model in complex with spiperone	109
<b>Figure 8.7(b)</b>	The 5-HT <sub>2A</sub> receptor model in complex with risperidone	109
<b>Figure 8.7(c)</b>	The 5-HT <sub>2A</sub> receptor model in complex with haloperidol	110
<b>Figure 8.7(d)</b>	The 5-HT <sub>2A</sub> receptor model in complex with ritanserin	110
<b>Figure 8.7(e)</b>	The 5-HT <sub>2A</sub> receptor model in complex with ketanserin	111
<b>Figure 8.8(a)</b>	Proposed binding mode of ( <i>S</i> )-bulbocapnine in the 5-HT <sub>2A</sub> receptor	113
<b>Figure 8.8(b)</b>	Proposed binding mode of ( <i>S</i> )-laureline in the 5-HT <sub>2A</sub> receptor	113
<b>Figure 8.8(c)</b>	Proposed binding mode of ( <i>S</i> )-nuciferine in the 5-HT <sub>2A</sub> receptor	114
<b>Figure 8.8(d)</b>	Proposed binding mode ( <i>R</i> )-apomorphine in the 5-HT <sub>2A</sub> receptor	114
<b>Figure 8.8(e)</b>	Proposed binding mode ( <i>S</i> )-apomorphine in the 5-HT <sub>2A</sub> receptor	115
<b>Figure 8.8(f)</b>	Proposed binding mode of ( <i>R</i> )- <i>N</i> -propylapomorphine in the 5-HT <sub>2A</sub> receptor	115
<b>Figure 8.8(g)</b>	Proposed binding mode of ( <i>R</i> )-2-hydroxy- <i>N</i> -propylapomorphine in the 5-HT <sub>2A</sub> receptor	116
<b>Figure 8.8(h)</b>	Proposed binding mode of ( <i>S</i> )-isocorydine in the 5-HT <sub>2A</sub> receptor	116
<b>Figure 8.8(i)</b>	Proposed binding mode of ( <i>S</i> )-isothebaine in the 5-HT <sub>2A</sub> receptor	117
<b>Figure 8.8(j)</b>	Proposed binding mode of ( <i>S</i> )-corydine in the 5-HT <sub>2A</sub> receptor	117

**Figure 8.8(k)** Proposed binding mode of (*S*)-corytuberine in the 5-HT<sub>2A</sub> 118  
receptor



## List of Tables

<b>Table 2.1</b>	Examples of some prescription drugs which target GPCRs for the indicated condition or disease state	5
<b>Table 2.2</b>	List of three dimensional crystal structures of GPCRs	7
<b>Table 3.1</b>	Computed $K_i$ values of the selected compounds	31
<b>Table 4.1</b>	Summary of the values used for the different parameters involved in optimising the protocols for the radioligand binding assays	43
<b>Table 4.2</b>	$K_i$ values of the standard ligands for $D_1$ , $D_2$ , 5-HT <sub>1A</sub> and 5-HT <sub>2A</sub> receptors	59
<b>Table 4.3</b>	Data from $Z'$ factor analysis for the $D_1$ , $D_2$ , 5-HT <sub>1A</sub> and 5-HT <sub>2A</sub> receptors	61
<b>Table 4.4</b>	Optimised assay conditions for $D_1$ , $D_2$ , 5-HT <sub>1A</sub> and 5-HT <sub>2A</sub> receptors	62
<b>Table 5.1</b>	Binding affinities of the selected ligands towards rat $D_1$ , $D_2$ , 5-HT <sub>1A</sub> and 5-HT <sub>2A</sub> receptors	69
<b>Table 5.2</b>	5-HT <sub>2A</sub> residues found from the docking studies to interact with the selected aporphines	74
<b>Table 8.1</b>	The ZINC IDs of the compounds selected from virtual screening	112

## List of Symbols and Abbreviations

2D	2 Dimensional
3D	3 Dimensional
5-HT	5-hydroxytryptamine, serotonin
5-HT <sub>1A</sub>	5-hydroxytryptamine <sub>1A</sub>
5-HT <sub>2A</sub>	5-hydroxytryptamine <sub>2A</sub>
5-MeOT	5-methoxytryptamine
8-OH-DPAT	(±)-8-hydroxy-2-(di- <i>n</i> -propylamino)-tetralin
[ <sup>3</sup> H] 8-OH-DPAT	8-Hydroxy-2-[2,3- <sup>3</sup> H]di- <i>n</i> -(propylamino)tetralin
[ <sup>3</sup> H] SCH 23390	[ <sup>3</sup> H] 7-chloro-8-hydroxy-3-methyl-5-phenyl-2,3,4,5-tetrahydro-1- <i>H</i> -3-benzazepine
aa	Amino acid
AMP	Adenosine monophosphate
APDs	Antipsychotic drugs
<i>B</i> <sub>max</sub>	Maximal binding capacity
BSA	Bovine serum albumin
cAMP	Cyclic adenosine monophosphate
CNS	Central nervous system
CV	Coefficient of variation
D <sub>1</sub>	Dopamine <sub>1</sub>
D <sub>2</sub>	Dopamine <sub>2</sub>
DOI	(±)-2, 5-dimethoxy-4-iodoamphetamine
DMSO	Dimethyl sulphoxide
ECL	Extracellular loop
EtOH	Ethanol

GF/B	Glass fibre type B
GF/C	Glass fibre type C
GPCR	G-protein coupled receptor
HCl	Hydrochloride
$IC_{50}$	Concentration at 50% inhibition
$K_d$	Equilibrium dissociation constant
$K_i$	Inhibition constant
[L]	concentration of radioligand
MDMA	Methylenedioxymethamphetamine
MeOH	Methanol
NSB	Nonspecific binding
PDB	Protein Data Bank
SAR	Structure activity relationship
SB	Specific binding
S/B	Signal to background ratio
SCH 23390	<i>R</i> -(+)-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine
SD	Standard deviation
SEM	Standard error mean
SBDD	Structure-based drug design
TB	Total binding
Tris	Tris(hydroxymethyl)aminomethane
UV	Ultraviolet
WHO	World Health Organization

## Units of Measurement

%	Percent
Å	Angstrom
°C	Degree celsius
C <sub>i</sub>	Curie
ε	Epsilon
× g	Times gravity
μg	Microgram
cpm	Count per minute
M	Molar
mg	Milligram
min	Minute
ml	Milliliter
mM	Millimolar
nM	Nanomolar
min	Minute
Rpm	Revolutions per minute
v/v	Volume per volume
w/v	Weight per volume

## List of Amino Acids

Ala (A)	Alanine
Arg (R)	Arginine
Asn (N)	Asparagine
Asp (D)	Aspartate
Cys (C)	Cysteine
Gln (Q)	Glutamine
Glu (E)	Glutamate
Gly (G)	Glycine
His (H)	Histidine
Ile (I)	Isoleucine
Leu (L)	Leucine
Lys (K)	Lysine
Met (M)	Methionine
Phe (F)	Phenylalanine
Pro (P)	Proline
Ser (S)	Serine
Thr (T)	Threonine
Trp (W)	Tryptophan
Tyr (Y)	Tyrosine
Val (V)	Valine